A 35-year-old man comes to the emergency department due to a 24-hour history of high fever… — USMLE Step 3

A 35-year-old man comes to the emergency department due to a 24-hour history of high fever, severe headache, photophobia, and nausea. Two months ago, he was evaluated for severe fatigue, episodic dark morning urine, and a recent hepatic vein thrombosis. At that time, flow cytometry of his peripheral blood demonstrated an absence of glycosylphosphatidylinositol (GPI)-anchored proteins, specifically CD55 and CD59, on the surface of his erythrocytes. He was subsequently started on a targeted monoclonal antibody therapy. Today, his temperature is $39.4^\circ\text{C}$ ( $102.9^\circ\text{F}$ ), blood pressure is $90/60\text{ mm Hg}$ , and pulse is $122/\text{min}$ . Physical examination reveals marked nuchal rigidity and a purpuric rash on the lower extremities. Cerebrospinal fluid analysis reveals a markedly elevated leukocyte count with a neutrophilic predominance, and Gram stain demonstrates intracellular Gram-negative diplococci. Which of the following best describes the immunologic mechanism of the patient's pharmacotherapy that directly led to his current presentation?

Blockade of C5 cleavage, preventing the assembly of the terminal membrane attack complexAnswer
B
Widespread consumption of early classical complement proteins, impairing bacterial opsonization
C
Depletion of CD20-positive B-lymphocytes, resulting in a profound secondary hypogammaglobulinemia
D
Disruption of alpha-4 integrin-mediated leukocyte transmigration across the blood-brain barrier
E
Inhibition of hepatic cytochrome P450 enzymes, causing rapid clearance of prophylactic antibiotics

Answer

The pharmacotherapy blocks C5 cleavage, which prevents the assembly of the terminal membrane attack complex.

The correct answer accurately describes the mechanism of eculizumab, the standard biologic therapy for Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is caused by an acquired mutation in the PIGA gene, leading to the absence of GPI-anchored proteins (CD55/decay-accelerating factor and CD59/MAC-inhibitory protein) that normally protect red blood cells from complement-mediated lysis. Eculizumab is a monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b. While this successfully halts the intravascular hemolysis by preventing the formation of the terminal membrane attack complex (MAC, C5b-9) on erythrocytes, it simultaneously creates a severe, acquired terminal complement deficiency. The MAC is immunologically essential for the lysis of thickly encapsulated bacteria, almost exclusively Neisseria species (e.g., N. meningitidis, N. gonorrhoeae). Consequently, patients on eculizumab are at a markedly increased risk of fulminant meningococcal meningitis and sepsis, requiring targeted vaccination prior to initiating therapy.

Step-by-Step Solution

Diagnose the patient's underlying condition based on the historical presentation.

The patient has Paroxysmal Nocturnal Hemoglobinuria (PNH).

The triad of hemolytic anemia (dark morning urine), pancytopenia/fatigue, and venous thrombosis (hepatic vein/Budd-Chiari syndrome) coupled with absent CD55/CD59 on flow cytometry is pathognomonic for PNH.

Identify the standard targeted pharmacotherapy for PNH.

Eculizumab is the indicated monoclonal antibody.

Eculizumab is a first-line biologic therapy that reduces hemolysis and the risk of thrombosis in patients with symptomatic PNH.

Determine the precise immunologic mechanism of this drug and its associated risks.

Eculizumab binds to C5, preventing its cleavage into C5a and C5b. This directly inhibits the formation of the membrane attack complex (MAC).

By blocking the terminal complement cascade, the drug prevents MAC-mediated destruction of the patient's red blood cells. However, because the MAC is critical for defense against encapsulated Neisseria species, patients are at extreme risk for severe meningococcal meningitis and sepsis.

Correlate the mechanism with the acute clinical presentation.

The patient's current presentation of meningitis with Gram-negative diplococci (Neisseria meningitidis) is a direct consequence of C5 blockade.

The inability to form the MAC due to C5 inhibition leaves the patient uniquely vulnerable to this specific pathogen.

Key Concept

Patients receiving terminal complement inhibitors (e.g., eculizumab) for Paroxysmal Nocturnal Hemoglobinuria are uniquely susceptible to invasive Neisseria meningitidis infections due to the inability to form the membrane attack complex (MAC).

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic